XYOSTED (AUTOINJECTOR) (Testosterone Enanthate) Patent Expiration, LOE Window & CMS Spending

XYOSTED (AUTOINJECTOR) (Testosterone Enanthate) by Antares: FDA Orange Book core substance LOE 2036-09-04, 0 AB generics, $0 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAntares
FDA Application & PathwayN209863 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2036-09-04
Last Listed Patent or Exclusivity Date2036-09-04
Orange Book Patents (*PED Extensions)69 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel